Ernexa Therapeutics (ERNAW) Common Equity (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Common Equity data on file, last reported at $6.9 million in Q1 2026.

• Quarterly Common Equity rose 215.28% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 215.28% YoY) and the FY2025 annual result came in at $2.4 million, up 41.15% from the prior year.
• Common Equity climbed to $6.9 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $17.3 million in Q1 2022 to a low of -$45.4 million in Q3 2024.
• A 5-year average of $1.5 million and a median of $3.6 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity tumbled 1374.37% — and 2026, when it jumped 215.28%.
• Tracing ERNAW's Common Equity over 5 years: stood at $12.1 million in 2022, then plunged by 81.56% to $2.2 million in 2023, then decreased by 23.82% to $1.7 million in 2024, then soared by 41.15% to $2.4 million in 2025, then surged by 185.67% to $6.9 million in 2026.
• The last three Common Equity figures came in at $6.9 million (Q1 2026), $2.4 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.